This report identifies the generic drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to generic drugs market.
Globally North America dominated the market for generic drugs in 2015 with highest market share due to easy availability of such drugs in the region along with regulations over prescription of branded drugs by governing authorities in the region. North America was followed by Europe as the second largest regional market for generic drugs. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to increasing awareness about generic drugs in the region.
This report on global generic drugs covers different type of generic drugs classes, and market size in various geographical regions.
On the basis of applications of generic drugs, this report also covers all the major generic drugs classes in curing major diseases, some of the major drug classes covered in this report are as follows: Cardiovascular Products, Anti-Infective Drugs, Anti-Arthritis Drugs, Central Nervous System Drugs, Anti-Cancer Drugs, Respiratory Products and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for generic drugs in each of the region.
This report identifies all the major companies operating in the global generic drugs market. Some of the major companies’ profiles in detail are as follows:
WATSON PHARMACEUTICALS, INC.
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
SANDOZ INTERNATIONAL GMBH
RANBAXY LABORATORIES, LTD.
PAR PHARMACEUTICAL, INC.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Generic Drugs – Market Forces
4.1.1. cost-effectiveness of generic drugs against branded drugs
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Generic Drugs – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Generic Drugs Market, By Drug Class
6.1. Cardiovascular Products
6.2. Anti-Infective Drugs
6.3. Anti-Arthritis Drugs
6.4. Central Nervous System Drugs
6.5. Anti-Cancer Drugs
6.6. Respiratory Products
7. Generic Drugs Market, By Geography
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.4. Rest of the World (RoW)
7.4.2. Rest of RoW
8. Generic Drugs – Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. WATSON PHARMACEUTICALS, INC.
9.2. TEVA PHARMACEUTICAL INDUSTRIES, LTD.
9.3. SANDOZ INTERNATIONAL GMBH
9.4. RANBAXY LABORATORIES, LTD.
9.5. PAR PHARMACEUTICAL, INC.
9.6. MYLAN INC.
9.7. HOSPIRA, INC.
9.8. DR. REDDY’S LABORATORIES, LTD.
9.9. APOTEX INC.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights